In-Hospital Cost-Consequence Analysis of Systemic Alteplase Versus Unfractionated Heparin in Intermediate-High-Risk Pulmonary Embolism

R analysis script (v5) and model outputs for: Marić N, Milošević M, Damjanović I, Duda M, Likić R. In-Hospital Cost-Consequence Analysis of Systemic Alteplase Versus Unfractionated Heparin in Intermediate-High-Risk Pulmonary Embolism: Hospital Expenditure and Reimbursement. Clinical Drug Investigation.CURRENT VERSION: the files in this version (v5_figshare.zip, README.txt) correspond to the second revision of the article and supersede all earlier versions. Hospital expenditure and Croatian Health Insurance Fund reimbursement are reported separately, using patient-level invoice data. Earlier versions (script v4) are retained in the version history for transparency only; their bed-day values were patient co-payment amounts and should not be used. See README.txt for contents, version history and reproducibility details. Patient-level data are not included for ethical reasons.